BST:2PD

Stock Analysis Report

Executive Summary

PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics using its Peptide Discovery Platform System.

Snowflake

Exceptional growth potential with flawless balance sheet.

Share Price & News

How has PeptiDream's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 2PD's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-10.7%

2PD

-2.3%

DE Biotechs

0.03%

DE Market


1 Year Return

19.3%

2PD

-6.9%

DE Biotechs

9.9%

DE Market

Return vs Industry: 2PD exceeded the German Biotechs industry which returned -6.9% over the past year.

Return vs Market: 2PD exceeded the German Market which returned 9.9% over the past year.


Shareholder returns

2PDIndustryMarket
7 Day-10.7%-2.3%0.03%
30 Day-5.0%-3.1%4.4%
90 Day-19.4%-9.6%13.6%
1 Year19.3%19.3%-6.7%-6.9%13.4%9.9%
3 Year69.3%69.3%52.7%50.8%25.6%14.6%
5 Year354.1%354.1%5.0%2.7%36.9%18.2%

Price Volatility Vs. Market

How volatile is PeptiDream's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is PeptiDream undervalued compared to its fair value and its price relative to the market?

226.35x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 2PD (€38.4) is trading above our estimate of fair value (€24.53)

Significantly Below Fair Value: 2PD is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 2PD is poor value based on its PE Ratio (226.3x) compared to the Biotechs industry average (29.8x).

PE vs Market: 2PD is poor value based on its PE Ratio (226.3x) compared to the German market (19.5x).


Price to Earnings Growth Ratio

PEG Ratio: 2PD is poor value based on its PEG Ratio (6.2x)


Price to Book Ratio

PB vs Industry: 2PD is overvalued based on its PB Ratio (33.7x) compared to the DE Biotechs industry average (3.1x).


Next Steps

Future Growth

How is PeptiDream forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

36.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 2PD's forecast earnings growth (36.5% per year) is above the savings rate (0.2%).

Earnings vs Market: 2PD's earnings (36.5% per year) are forecast to grow faster than the German market (12.5% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 2PD's revenue (31.7% per year) is forecast to grow faster than the German market (4.8% per year).

High Growth Revenue: 2PD's revenue (31.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 2PD's Return on Equity is forecast to be high in 3 years time (33.7%)


Next Steps

Past Performance

How has PeptiDream performed over the past 5 years?

34.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 2PD has high quality earnings.

Growing Profit Margin: 2PD's current net profit margins (36.2%) are lower than last year (44.3%).


Past Earnings Growth Analysis

Earnings Trend: 2PD's earnings have grown significantly by 34% per year over the past 5 years.

Accelerating Growth: 2PD's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 2PD had negative earnings growth (-15.4%) over the past year, making it difficult to compare to the Biotechs industry average (5.4%).


Return on Equity

High ROE: 2PD's Return on Equity (14.8%) is considered low.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is PeptiDream's financial position?


Financial Position Analysis

Short Term Liabilities: 2PD's short term assets (¥9.0B) exceeds its short term liabilities (¥1.3B)

Long Term Liabilities: 2PD's short term assets (9.0B) exceeds its long term liabilities (149.0M)


Debt to Equity History and Analysis

Debt Level: 2PD is debt free.

Reducing Debt: 2PD has not had any debt for past 5 years.

Debt Coverage: 2PD has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 2PD has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: 2PD has a high level of physical assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 2PD's debt is covered by short term assets.


Next Steps

Dividend

What is PeptiDream's current dividend yield, its reliability and sustainability?

0.016%

Forecast Dividend Yield


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.7%industryaverage1.1%forecastin3Years0.02%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate 2PD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 2PD's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 2PD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 2PD's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 2PD's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of PeptiDream's salary, the management and board of directors tenure and is there insider trading?

4.8yrs

Average board tenure


CEO

Patrick Reid (44yo)

0yrs

Tenure

0

Dr. Patrick Crawford Reid, Ph.D. has been President of PeptiDream Inc. since October 10, 2017 and serves as its CEO. Dr. Reid served as Head of R&D and Senior Vice President at PeptiDream Inc. until Octobe ...


Board Age and Tenure

4.8yrs

Average Tenure

58yo

Average Age

Experienced Board: 2PD's board of directors are considered experienced (4.8 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Management Team

  • Patrick Reid (44yo)

    President & CEO

    • Tenure: 0yrs
  • Keiichi Masuya (50yo)

    Executive VP & Director

    • Tenure: 4.8yrs
  • Kiyofumi Kaneshiro

    Executive VP & Director

    • Tenure: 1.8yrs

Board Members

  • Kiichi Kubota (66yo)

    Chairman of the Board

    • Tenure: 0yrs
  • Patrick Reid (44yo)

    President & CEO

    • Tenure: 0yrs
  • Michio Sasaoka (70yo)

    External Director

    • Tenure: 0yrs
  • Keiichi Masuya (50yo)

    Executive VP & Director

    • Tenure: 4.8yrs
  • Yukinori Hanafusa (44yo)

    External Director

    • Tenure: 0yrs
  • Toshio Nagae (76yo)

    External Director

    • Tenure: 0yrs
  • Kiyofumi Kaneshiro

    Executive VP & Director

    • Tenure: 1.8yrs

Company Information

PeptiDream Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: PeptiDream Inc.
  • Ticker: 2PD
  • Exchange: BST
  • Founded: 2006
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: JP¥582.652b
  • Listing Market Cap: JP¥4.846b
  • Shares outstanding: 125.17m
  • Website: https://www.peptidream.com

Number of Employees


Location

  • PeptiDream Inc.
  • 3-25-23 Tonomachi
  • Kawasaki-ku
  • Kawasaki
  • Kanagawa
  • 210-0821
  • Japan

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
4587TSE (The Tokyo Stock Exchange)YesCommon StockJPJPYJun 2013
2PDBST (Boerse-Stuttgart)YesCommon StockDEEURJun 2013
PPTD.FOTCPK (Pink Sheets LLC)YesCommon StockUSUSDJun 2013

Biography

PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics using its Peptide Discovery Platform ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/16 21:38
End of Day Share Price2019/11/15 00:00
Earnings2019/09/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.